Metabolic Aggressiveness in Benign Meningiomas with Chromosomal Instabilities

Daniel Monleón1, José Manuel Morales2, Ana González-Segura3, José Manuel González-Darder4, Rosario Gil-Benso3, Miguel Cerdá-Nicolás3,5, and Concepción López-Ginés3

Abstract

Meningiomas are often considered benign tumors curable by surgery, but most recurrent meningiomas correspond to histologic benign tumors. Because alterations in chromosome 14 among others have suggested clinical aggressiveness and recurrence, determining both the molecular phenotype and the genetic profile may help distinguish tumors with aggressive metabolism. The aim of this study was to achieve higher specificity in the detection of meningioma subgroups by measuring chromosomal instabilities by fluorescence in situ hybridization and cytogenetics and metabolic phenotypes by high-resolution magic angle spinning spectroscopy. We studied 46 meningioma biopsies with these methodologies. Of these, 34 were of WHO grade 1 and 12 were of WHO grade 2. Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities. The metabolic phenotype of this subgroup indicated an aggressive metabolism resembling that observed for atypical meningioma. According to the metabolic profiles, these tumors had increased energy demand, higher hypoxic conditions, increased membrane turnover and cell proliferation, and possibly increased resistance to apoptosis. Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors. Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.

Introduction

Meningiomas are often considered benign tumors curable by surgery. However, ~20% of meningiomas with histologic low grade may be clinically aggressive and recur (1). Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15% to 20% of all central nervous system tumors. The current standards for diagnosis of meningiomas are clinical and pathologic findings. The WHO classifies meningiomas into three histologic grades: grade 1 (benign), grade 2 (atypical), and grade 3 (anaplastic), in accordance with the clinical prognosis (2). Signs of malignancy in meningioma include marked vascularity, loss of organoid structure, mitotic figures, nuclear pleomorphism, prominent nucleoli, focal necrosis, or infiltration to the adjacent brain. Atypical and anaplastic meningiomas show a high index of recurrence 5 years after complete resection and are associated with lower survival rates compared with benign meningiomas (3). However, in absolute numbers, most recurrent meningiomas correspond to histologic benign tumors. The potential aggressiveness of an individual meningioma is still difficult to evaluate.

The genesis of meningiomas has been associated with loss of genetic material on chromosome 22. Monosomy of this chromosome is the most common genetic alteration in meningioma and was one of the first cytogenetic alterations described in solid tumors (4, 5). Loss of 1p and alterations in chromosome 14 are present in many atypical meningioma (6). Losses in 6q, 10, and 18q and gains on 1q, 9q, 12q, 15q, 17q, and 20q are also common in atypical meningioma (7). Based on this information, genetic characterization of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.

We studied 46 meningioma biopsies with these methodologies. Of these, 34 were of WHO grade 1 and 12 were of WHO grade 2. Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities. The metabolic phenotype of this subgroup indicated an aggressive metabolism resembling that observed for atypical meningioma. According to the metabolic profiles, these tumors had increased energy demand, higher hypoxic conditions, increased membrane turnover and cell proliferation, and possibly increased resistance to apoptosis. Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors. Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors.

Authors’ Affiliations: 1Fundación de Investigación del Hospital Clínico Universitario de Valencia/INCLIVA; 2Unidad Central de Investigación en Medicina and 3Departamento de Patología, Universitat de València; 4Servicio de Neurocirugía, Hospital Clínico Universitario de Valencia, Valencia, Spain; and 5Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain

Corresponding Author: Daniel Monleón, Fundación de Investigación del Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez, 17, Valencia 46010, Spain. Phone: 34–963983225; Fax: 34–963987860; E-mail: daniel_monleon@uv.es.

doi: 10.1158/0008-5472.CAN-10-1498

©2010 American Association for Cancer Research.
will improve these clinical decisions as well as patient follow-up strategy after surgery.

Metabolomics is defined as “the quantitative measurement of the multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification” (9). High-resolution nuclear magnetic resonance (NMR) spectroscopy of biofluids and tissues combined with multivariate analysis methodologies, such as principal component analysis (PCA), represent a powerful technique for investigating the metabolome in the area of drug toxicology and disease diagnosis and prognosis (10). NMR is one of the most efficient, robust, reproducible, and cheap methods for obtaining metabolic profiles in biological specimens without extensive sample preparation (11). High-resolution magic angle spinning (HR-MAS) NMR spectroscopy is a powerful technique for the investigation of metabolites within different intact tissues (12–16). The potential of HR-MAS applications to the study of biological tissues has been widely shown in the investigation of different cellular alterations. In addition, HR-MAS NMR spectroscopy of intact tissues (ex vivo) provides further advantages over traditional high-resolution liquid NMR of tissue extracts (in vitro). This technology can supplement histopathologic examination and potentially improve brain tumor diagnostics. HR-MAS spectra generate metabolic profiles that contain information on physiologic and pathologic status. This approach can be used to define the metabolomic phenotype of a tissue.

The aim of this study was to detect new subgroups of meningoima and to achieve higher specificity in the classification of meningoima by measuring metabolic phenotypes with high-resolution NMR spectroscopy. We collected HR-MAS spectra on 34 benign and 12 atypical meningoima samples and used multivariate analysis for detecting metabolic subgroups. Histopathology after NMR, which is essential validation of our results. This analysis shows that genetic instability has high effect on the metabolic profile of meningoima samples.

Materials and Methods

Patients and clinical samples

Forty-six human meningoima biopsies were obtained from 46 patients at the Department of Neurosurgery of the Clinical University Hospital of Valencia. This study was reviewed and approved by the local ethics committee. During surgery, most of the resected tissue was sent for routine histologic analysis, and the remainder was immediately put in cryogenic vials and snap frozen in liquid nitrogen. All snap-frozen samples were stored in a freezer at −80°C until further analysis. All samples used for histopathologic examination were fixed in neutral-buffered formalin, embedded in paraffin, sectioned, and stained with H&E. Tumors were classified according to the 2007 WHO histologic classification (2). Meningoima types analyzed include 34 benign meningoima (grade 1) and 12 atypical meningoima (grade 2).

Cytogenetic analysis and fluorescence in situ hybridization

Cytogenetic analyses were performed by short-term culture of the tumors. Fresh tumor samples were disaggregated with 2 mg/mL of collagenase II. The cells were seeded in flasks using RPMI 1640 supplemented with 20% fetal bovine serum, L-glutamine, and antibiotics. The cells were processed after 72 hours of culture by a standard technique. Air-dried slides were banded by trypsin-Giemsa. Karyotypic analyses were performed according to ISCN (17). The samples of meningoima used for fluorescence in situ hybridization (FISH) analysis were studied by tissue microarrays. We removed four 0.6-mm cores from the corresponding areas on the paraffin block in each case using the Beecher Instruments Manual Tissue Arrayer. For the investigation of chromosome abnormalities by interphase FISH, the probes LSI 22q12, LSI 1p36/LSI 1q25, and LSI t(11;14) IGH/CCND1 (Vysis, Inc.) were used.

Hybridizations were performed according to the instructions that accompany the probe. Counterstaining of nuclei was carried out using 4′,6-diamidino-2-phenylindole. The fluorescent signal was detected using a photomicroscope Axioplan 2 and Axiophot 2 (Zeiss) equipped with a set of the appropriate filters. For each hybridization, green and orange signals were counted in the four regions of a total of 100 to 200 nonoverlapping nuclei. An interpretation of deletion or imbalance was made when >20% of the nuclei harbored these alterations (18, 19). Cutoffs for deletions were based on the frequencies of signals for the same probes in nonneoplastic brain controls (median, ±3) and ranged from 14% to 21% for chromosome 1, from 16% to 22% for chromosome 14, and from 15% to 20% for monosomy 22. We considered deletion when one or less signal for chromosome appeared with respect to the signal of control (ratio, 0/1, 0/2, 1/2, 1/3...), and we considered normal with the probes used present a ratio 2/2.

HR-MAS spectroscopy

Total sample preparation time for each sample before NMR detection was <5 minutes. All the material to be in contact with the tissue was precooled to reduce tissue degradation during the sample preparation process. Frozen samples were taken from the ultrafreezer and immediately placed in a cryovial and in liquid N2 until insertion in a 4-mm outer diameter ZrO2 rotor. The HR-MAS tissue sample was split from the whole frozen tumoral mass submerged in liquid nitrogen. The precooled rotor was filled with cooled D2O after tissue sample insertion. Cylindrical inserts were used in all the cases, limiting the rotor inner volume to 50 μL. Exceeding D2O was removed before rotor sealing. Tissue samples were weighted in the rotor before D2O addition and HR-MAS measurements. Tissue fragments were weighted exclusively for sample preparation purposes. The mean sample weight was 27 ± 11 mg. Immediately after the measurement, the HR-MAS samples were fixed in formalin for subsequent histopathologic examination and for tumor content assessment by an expert pathologist.

All spectra were recorded in a Bruker Avance DRX 600 spectrometer operating at a 1H frequency of 600.13 MHz.
The instrument was equipped with a 4-mm triple resonance $^{1}H/^{13}C/^{15}N$ HR-MAS probe with magnetic field gradients aligned with the magic angle axis. For all experiments, samples were spun at 5,000 Hz to keep the rotation sidebands out of the acquisition window. Lock homogeneity was achieved by extensive coil shimming using the one-dimensional water presaturation experiments in interactive mode as control. Alanine doublet at 1,475 ppm was used for lock homogeneity shimming, as described elsewhere (20). Nominal temperature of the sample receptacle was kept at 273 K using the cooling of the inlet gas pressures responsible for the sample spinning. This value corresponded to the temperature measured from the thermocouple just below the rotor in the probe. The effect of sample rotation was to slightly increase this value. Internal measurement using a 100% methanol sample in a 4-mm rotor spinning at the same frequency provided a corrected internal value of 277 K. To minimize the effects of tissue degradation, which would alter the metabolite composition of the biopsy, all ex vivo spectra were acquired at this temperature of 277 K. A total of 10 minutes was allowed for the temperature of the sample to reach steady state before spectra were acquired. A single-pulse presaturation experiment was acquired in all the samples. The number of transients was 256 collected into 32 K data points for all the experiments. Water presaturation was used during 1 second along the recycling delay for solvent signal suppression. Spectral widths were 8,000 Hz for 1 hour. Before Fourier transformation, the free induction decay was multiplied with a 0.3-Hz exponential line broadening. Chemical shift referencing was performed relative to the alanine CH$_3$ signal at 1,475 ppm. For assignment purposes, two-dimensional (2D) homonuclear (2D-TOCSY) and heteronuclear (2D-$^{1}H$, $^{13}C$-HSQC) experiments were acquired on selected samples.

**NMR data analysis**

All 30 spectra were processed using MNova 5.3 (MestreLab S.A.) and transferred to MATLAB (MathWorks, Inc.) using in-house scripts for data analysis. All multivariate analysis was performed using the PLS_Toolbox library. The chemical shift region including resonances between 0.50 and 4.60 ppm and between 5.20 and 10.50 was investigated. For comparison of global metabolic profiles from different meningioma subgroups, the spectra were binned into 0.01 ppm buckets, normalized to total spectral integral, and subsequently analyzed by PCA. The spectral binning and normalization minimized the effect of differences in tissue weight and cell content for the different biopsies. We cross-validated our PCA model by performing 10 technical replicates by choosing random training (36 samples) and validation (10 samples) data subsets. Cross-validation is a technique for assessing how the results of a statistical analysis will generalize to an independent data set. The first two principal components of the average model (PC1 and PC2) accounted for a total of 65% of the variance in the spectral data set. Lower-order principal components did not provide clear differences between subgroups and consequently were not further analyzed. Spectral signal integration by peak-fitting algorithms over relevant resonances provided relative levels of the corresponding metabolites. Only those signals with peak-fitting residual error lower than 10% were used in the study.

**Statistical analysis**

To determine individual metabolic differences between the different subgroups of meningioma, univariate Student’s $t$ tests were performed for each signal of the individual metabolites detected as major contributor in the PCA analysis. We calculated the maximum false discovery rate (FDR) of the metabolites selected to account for multiple testing. FDR was estimated using the $q$ value statistical parameter (21). The $q$ value gives the estimated FDR for every possible list of significant signals. The $q$ value is based on estimating the true proportion of null hypotheses. The $P$ value histogram width used for calculating $q$ values was 0.005. Because we performed three comparisons and the $q$ value may be different, the $q$ value was applied separately to the $P$ values of each comparison. Unless otherwise indicated, the limit of $q$ value for metabolites selected in each comparison was set to 0.05 (FDR of 5%).

**Results**

**Histopathology**

Histologic analysis of the tissue specimens after HR-MAS analysis showed various amounts of tumor tissue (Fig. 1). In all cases, histologic analysis of the HR-MAS sample agreed with the histopathology original diagnosis. All samples included a percentage of tumor cells at least of 80%, as evaluated by two expert pathologists exploring at 10× the whole sample (1–2 mm), confirming that samples are representative of the tumor, independently of tumor grade.

**Chromosomal profile**

Karyotyping was obtained in 37 cell cultures from 37 different cases. Sample material was adequate for FISH studies in 42 cases. Information from both methodologies was combined to distinguish complex chromosomal profiles. Thirty-seven of 46 meningiomas presented clonal numerical and/or structural abnormalities, as shown in Table 1 and Supplementary Materials and Methods. All cases without chromosomal aberrations belonged to the histologic grade 1 meningioma group. Monosomy of chromosome 22 is the most common genetic alteration in meningioma and was detected in 22 of all cases. All cases without a complex karyotype were of histologic grade 1. Similarly, all those cases with alterations in chromosome 22, the only chromosomal anomaly were also of histologic grade 1. According to FISH chromosomal analysis, only 16% (5 of 32) of benign meningiomas are $-1p$, whereas this percentage rises to 70% (7 of 10) in atypical meningioma. All cases containing alterations in chromosome 14 were of histologic grade 2. All grade 2 meningiomas showed a complex karyotype, with six of them showing chromosomal alterations different to $-1p$, $-22$, and/or $-14$. These findings confirm that exploration of chromosomes beyond 1, 14, and 22 is recommended for genetic characterization of meningiomas. Our results show that meningiomas with higher histologic grade (grade 2) are very
likely to have a complex karyotype. There is a subpopulation of meningiomas with histologic grade 1, which also exhibits complex karyotype, despite not having alterations in chromosome 14. Besides 1, 14, and 22, chromosomes affected either in this benign meningioma subgroup or in atypical meningioma include 2, 3, 5, 7, 9, 10, 17, and 18. Differently to some previous studies, the combined use of FISH and cytogenetics allowed the detection of many different anomalous chromosomal profiles. Based on chromosomal profiles, we defined three meningioma subgroups for subsequent analysis: histologic grade 1 with normal or diploid karyotype (benignA), histologic grade 1 with complex karyotype (benignB), and histologic grade 2 (atypical).

**Metabolic profile**

HR-MAS spectroscopy provided well-resolved spectra of intact meningioma tissue samples. NMR spectra of benignA, benignB, and atypical meningioma are displayed in Fig. 1. The PCA analysis (Fig. 2) showed partial group separation between meningiomas benignA and meningiomas with

Table 1. Summary of chromosomal instabilities detected in benign and atypical meningioma according to cytogenetic and FISH analysis

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>-22</th>
<th>-1p</th>
<th>-14</th>
<th>Others*</th>
<th>Nonclonal†</th>
<th>-22q</th>
<th>-1p</th>
<th>-14q</th>
<th>Diploid</th>
</tr>
</thead>
<tbody>
<tr>
<td>BenignA</td>
<td>8</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>5</td>
<td>7</td>
<td>2</td>
</tr>
<tr>
<td>BenignB</td>
<td></td>
<td></td>
<td>3</td>
<td>9</td>
<td>13</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Atypical</td>
<td></td>
<td></td>
<td>6</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

NOTE: Cells in gray show the chromosomal instability progression in the different subgroups of meningioma.

*Numerical or structural alterations different to monosomy 22, 1p deletion, and monosomy 14 (see Supplementary Materials and Methods).

†Numerical or structural alterations, which are present only once in the different metaphases analyzed.
complex karyotype (benignB and atypical). On the other hand, histologic benign and atypical meningiomas formed two partially overlapping groups. The overlapping region contained most of the meningioma tumors showing chromosomal instabilities, indicating metabolic similarity between benign meningiomas with chromosomal instabilities (benignB subgroup) and the more aggressive atypical meningioma tumors. In the next step, individual metabolites were identified in the PCA loading plot and quantified for further analysis. A total of 19 metabolites showed statistically significant differences between either two of the three subgroups (Table 1). No statistically significant correlation was detected between FISH quantitative data (see Supplementary Materials and Methods) and the metabolic profiles (Table 2).

The major features for separation between benignA meningioma and atypical meningioma (the two subgroups clearly separated in the PCA scores plot) were higher concentrations of glycine, glutamate, total glutathione, lactate, taurine, phosphocholine, phosphoethanolamine, and uracil and lower concentrations of global fatty acids, γ-aminobutyric acid, ascorbate, acetate, creatine, alanine, leucine, isoleucine, glutamine, ascorbate, lysine, glucose, choline, and ethanolamine. For most of these metabolites, with the exception of taurine, glutamine, and γ-aminobutyric acid, the values for benignB meningioma were closer to atypical meningioma than to benignA meningioma (Table 1; Fig. 3). Meningioma with complex karyotype showed increased levels of glutamate and total glutathione and reduced levels of lactate, suggesting an increase in total glutathione production. Glucose, ascorbate, acetate, and fatty acids (metabolites involved in the tricarboxylic acid cycle) and fatty acid β-oxidation were all decreased in the same groups. Conversely, lactate was higher in atypical meningioma. Increased glucose uptake and high glycolytic activity, due to high energy requirement, are major hallmarks of tumor metabolism. These changes usually result in decreased intracellular glucose concentrations and higher levels of lactate. However, these metabolites may also be altered by the biopsy extraction procedure. Phosphocholine and phosphoethanolamine, both phospholipid derivatives, also showed increased levels in meningioma groups with complex karyotype. Increased membrane metabolite turnover is another significant metabolic pathway for tumor development and aggressiveness. On the other hand, the similar levels of polyunsaturated and monounsaturated fatty acids in all groups suggested a similar amount of necrotic fraction in the tissue. Finally, despite high variability, uracil metabolites increased with complex karyotype progressively and in a statistically significant manner. This suggests that nucleotide metabolism is also altered in more aggressive tumors.

**Discussion**

Most meningiomas are classified as benign based on clinical and pathologic findings. Nonetheless, the behavior of individual meningioma is still difficult to predict. Many previous studies report some correlation between chromosomal alterations and meningioma clinical outcome. Typically, these correlations are usually weak because of two reasons. First, the chromosomal profile typically is limited to FISH analysis of a few chromosomes. Second, clinical outcome takes years to be properly assessed and still many individuals may exhibit the clinical aggressiveness later on. Maillo and colleagues (22) show that statistical correlation between genetic abnormalities and clinical outcome improves when follow-up is extended to 10 years, with a subset of patients showing recurrence 15 years after surgery. On the other hand, most of the previously reported meningioma subgroups define aggressiveness based solely on WHO grade and morphologic parameters. This definition of the phenotype of an aggressive meningioma is rather poor. The metabolic changes of any cell population precede morphologic changes. In fact, chromosomal alterations produce changes in the metabolic phenotype almost immediately. The measurement of a metabolic phenotype at the moment of the histopathologic diagnosis may help in detecting better defined molecular meningioma subgroups.

In our study, chromosomal profiling by cytogentic and FISH and metabolic profiling by NMR spectroscopy on benign and atypical meningioma reveal distinct molecular phenotypes that allowed detecting metabolic aggressiveness in these tumors. Previous studies on metabolic profiling of meningiomas report weak correlations between grade and metabolic phenotype (19, 23). This may be due to the use of tissue extracts, which precludes the histopathology of the sample and makes impossible to know the tumor content, leading to much broader variability in the metabolite levels. To our knowledge, this is the first combined genetic and metabolic analysis of intact biopsies of benign and atypical meningiomas for detecting metabolic subgroups. The use of cytogentic allows the detection of a global chromosomal profile. Similarly, NMR spectroscopy combined with multivariate analysis provides a global metabolic profile. The combination of these data provides a robust and well-delimited set of meningioma subgroups.
Chromosomal aberrations in a tumor sample are typically studied by FISH. FISH is a target-oriented method that allows direct observation of specific chromosomal abnormalities. It is more sensitive than standard cytogenetic methods because it does not require dividing cells and can be measured directly in the tumor tissue. However, cytogenetic methods provide a whole-genome chromosomal profiling and may reveal chromosomal alterations in regions different to those explored by target-oriented methods. The combination of both methods provides a global chromosomal profile with high sensitivity in specific regions. Therefore, we found chromosomal alterations that would not have been detected by any of the individual approaches alone. We chose to examine chromosomes 1, 14, and 22 by FISH because aberrations of those chromosomes are the most frequently reported genetic abnormalities in meningioma (7). Our findings confirmed that loss of 1p and/or 14 are the most common chromosomal alterations in atypical meningioma. Coexistence of monosomy 14 and 1p is a powerful adverse prognostic factor for early relapses (6). However, meningiomas are cytogenetically heterogeneous tumors. The detection of a subset of benign meningiomas with chromosomal alterations beyond monosomy 22 may have an important effect in defining aggressiveness in meningiomas. This subset of benign meningiomas (benignB subgroup) shows a wide variety of chromosomal alterations, all producing a complex karyotype. Histologic benign meningiomas with complex karyotype have higher probability of relapsing (22). In line with this, in the present study, all histologic benign meningiomas with complex karyotype (subgroup benignB) show a metabolic phenotype similar to that of atypical meningioma.

The metabolic phenotype of meningiomas with complex karyotype shows typical features of aggressive tumor biochemistry such as increased membrane metabolite turnover and high glycolytic activity. Lower levels of glucose and ascorbate together with higher levels of lactate suggest higher dependence on anaerobic breakdown of pyruvate for meningiomas with complex karyotype. Lactate accumulation also creates a microenvironment that may enhance cell proliferation (24). Lower glucose levels in cells of more aggressive tumors may reflect preferential glucose consumption and a local hypoxic microenvironment. Hypoxia in the tumor microenvironment triggers a variety of genetic and adaptive responses that regulate tumor growth (25). Tumor hypoxia is often associated with more malignant phenotypes, resistance to therapy, and poor survival. Another metabolite closely related to energy metabolism is creatine. Total creatine is lower in meningiomas with chromosomal instabilities. This

### Table 2. Resonance intensity ratios, SDs, and P values from most relevant metabolites in the classification of benign and atypical meningiomas

<table>
<thead>
<tr>
<th>Metabolite (peak position)</th>
<th>Relative intensity (arbitrary units)</th>
<th>BenignA vs BenignB</th>
<th>BenignA vs atypical</th>
<th>BenignB vs atypical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatty acids (0.89 ppm)</td>
<td>73 ± 24 45 ± 18 52 ± 21</td>
<td>0.008 0.016 0.388</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leucine (0.97 ppm)</td>
<td>45 ± 15 30 ± 10 34 ± 12</td>
<td>0.019 0.072 0.333</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isoleucine (1.02 ppm)</td>
<td>28 ± 7 20 ± 6 23 ± 7</td>
<td>0.008 0.011 0.141</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactate (1.33 ppm)</td>
<td>211 ± 121 302 ± 99 341 ± 132</td>
<td>0.028 0.008 0.401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alanine (1.48 ppm)</td>
<td>58 ± 24 29 ± 18 31 ± 17</td>
<td>0.001 0.002 0.797</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetate (1.92 ppm)</td>
<td>21 ± 8 16 ± 8 15 ± 7</td>
<td>0.078 0.032 0.662</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutamate (2.35 ppm)</td>
<td>23 ± 4 27 ± 7 31 ± 8</td>
<td>0.014 0.265 0.037</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutamine (2.44 ppm)</td>
<td>30 ± 9 30 ± 18 23 ± 5</td>
<td>0.978 0.059 0.256</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total glutathione (2.55 ppm)</td>
<td>12 ± 6 17 ± 4 17 ± 8</td>
<td>0.081 0.009 0.913</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine (3.03 ppm)</td>
<td>48 ± 22 29 ± 17 25 ± 13</td>
<td>0.011 0.004 0.595</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethanolamine (3.15 ppm)</td>
<td>10 ± 3 8 ± 3 7 ± 3</td>
<td>0.051 0.012 0.150</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choline (3.19 ppm)</td>
<td>43 ± 12 30 ± 12 29 ± 15</td>
<td>0.012 0.011 0.731</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphocholine (3.22 ppm)*</td>
<td>61 ± 35 82 ± 28 91 ± 40</td>
<td>0.077 0.043 0.551</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taurine (3.26 ppm)</td>
<td>25 ± 8 26 ± 8 32 ± 9</td>
<td>0.745 0.025 0.064</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glycine (3.55 ppm)</td>
<td>26 ± 8 30 ± 7 34 ± 9</td>
<td>0.361 0.030 0.167</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (3.88 ppm)</td>
<td>41 ± 17 36 ± 14 28 ± 11</td>
<td>0.317 0.011 0.095</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphoethanolamine (4.01 ppm)</td>
<td>14 ± 7 15 ± 6 23 ± 9</td>
<td>0.839 0.008 0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ascorbate (4.52 ppm)†</td>
<td>2 ± 1 — —</td>
<td>— — 0.983</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uracil (7.54 ppm)†</td>
<td>— 2 ± 1 —</td>
<td>— — 0.983</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** Most of the metabolites show values for BenignB meningioma closer to atypical than to BenignA meningioma, suggesting metabolic aggressiveness in this subgroup.

* q > 0.05.
† Signal intensity was not sufficient for quantification in all the samples.
may indicate either lower substrate availability or increased ATP usage, which suggests an environment with high energy demand. Finally, the decreased levels of fatty acids may also reflect increased β-oxidation. All these processes result in a metabolically unfavorable microenvironment with low glucose availability and local hypoxic conditions. Our results suggest that meningiomas with chromosomal instabilities have this energy-demanding microenvironment.

Choline-containing compounds are elevated in tumors (26, 27). Phosphocholine and choline compounds are generally considered as well-established proliferation markers. In addition, high phosphocholine is also correlated with highly invasive phenotypes. However, these compounds are not easily detected by conventional high-resolution NMR. The tissue extraction process disables the direct observation of small cellular proteins and membrane semimobile phospholipids precursors. On the contrary, HR-MAS allows the determination of these important metabolites in intact biopsies. Meningiomas with chromosomal instabilities have higher phosphocholine levels, which are consistent with higher energy-demanding microenvironment.

Figure 3. Histograms showing relevant metabolite levels, SD error bars, and significance levels (*, P < 0.05; **, P < 0.02; ***, P < 0.01) for the benign meningioma without chromosomal instabilities (subgroup benignA, black columns), the benign meningioma with chromosomal instabilities (subgroup benignB, gray columns), and the atypical meningioma (white columns). FA, fatty acids; Glc, glucose; Ace, acetate; Lac, lactate; Ala, alanine; Cre, creatine; Gsx, total glutathione; Tau, taurine; Cho, choline; EA, ethanolamine; PCho, phosphocholine; PEA, phosphoethanolamine.

Figure 4. Scheme showing the interconnection between the different metabolites and processes involved in the metabolic aggressiveness observed for the benign meningioma with chromosomal instabilities. Essentially, the metabolic differences observed in benign meningioma with chromosomal instabilities with respect to other benign meningioma suggest higher energy demand and metabolic activity, higher proliferation rates, higher antioxidant capacity, and higher hypoxia, which are indicative of more aggressive tumors.
Metabolic Aggressiveness in Meningioma Subgroups

proliferative rates. In addition, phosphoethanolamine, which is also considered as an intermediate in the metabolism of phospholipids, exhibits increased levels in meningioma with chromosomal instabilities. A high relative intensity of the phosphoethanolamine resonance in 31P MR spectroscopy is a reported marker for malignancy (28). Increased phosphoethanolamine levels suggest an activation of phosphatidylethanolamine metabolism, which is involved in the modification of membrane shape in malignant tissue (29). Additionally, free phosphoethanolamine might reflect the breakdown of phosphatidylethanolamine to diacylglycerol, and might act as a long-term second messenger for cell proliferation (30).

Glutathione is an important cell antioxidant and, in normal tissues, plays different roles in protection against oxidative damage (31), in apoptosis (32–34), and in amino acid transport (35). Glutathione depletion is a common feature of apoptotic cell death. In cancer, glutathione is able to play both protective and pathogenic roles (31). In addition, there is a correlation between decreased total glutathione levels and cell differentiation. In meningioma, levels of glutathione and closely related metabolites, such as glutamate, are increased with respect to other brain tumors and healthy brain tissue (36). A potential explanation for this is the reversible transamination reaction of alanine and α-ketoglutarate, synthesizing glutamate, as an alternative energy source. This may also explain the lower levels of alanine in atypical meningioma despite higher hypoxic conditions. Another source of glutamate is glutamine by the glutaminase reaction, which also explains the lower levels found for glutamine in the same subgroup. Meningioma with chromosomal instabilities shows increased levels of glutathione and glutamate and decreased levels of alanine and glutamine, which suggest less cell differentiation, resistance to apoptosis, and activation of alternative energy sources.

The aforementioned metabolites and pathways play critical roles in cancer metabolism. All of them suggest that meningiomas with chromosomal instabilities suffer metabolic alterations related to aggressiveness, proliferation, and invasiveness (see Fig. 4 for a schematic view). Other metabolic changes reported here are also in the same line. For example, glycine, which is the simplest nonessential amino acid and is associated to recurrence in some brain tumors (37), is increased in meningioma with complex karyotype. Glycine is a major component of collagen. Increased levels of glycine suggest increased collagen synthesis and artery wall formation, and therefore sustained angiogenesis. Increased levels of uracil in meningioma with chromosomal instabilities may reflect the activation of uracil glycosylase, which excises uracil from DNA deaminated cytosine and repairs damaged DNA. Previous studies reported that uracil glycosylase activity correlates with tumor recurrence (38).

In summary, the metabolic phenotype detected by HR-MAS in meningioma allows detecting metabolic aggressiveness in histologic benign tumors. The multivariate analysis shows that benign meningioma with complex karyotype (benignB subgroup) is metabolically closer to atypical meningioma than to other benign meningiomas (benignA subgroup). Most of the metabolites showing statistically significant differences between groups suggest a more aggressive biochemistry in meningiomas with chromosomal instabilities regardless of their histologic grade. To our knowledge, this is the first time that distinct metabolic phenotypes are reported for otherwise benign meningiomas based on cytogenetic studies and multivariate analysis and global metabolic profiling of intact tumor biopsies. Overall, this work shows that the measurement of a metabolic phenotype in meningioma intact biopsies simultaneously to the histopathology analysis may allow the early detection of metabolically aggressive tumors.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

Consellería de Sanidad (GV-AP064/07, GV-AP076/08, and GV-AP014/09) and the Conselleria de Educación (ACOMP2009-200) de la Generalitat Valenciana, the Ministerio de Educación y Ciencia del Gobierno de España (SAF2008-00270). D. Monleón gratefully acknowledges the Ministerio de Educación y Ciencia del Gobierno de España for a Ramón y Cajal 2006 Contract.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/28/2010; revised 09/14/2010; accepted 09/14/2010; published OnlineFirst 09/21/2010.

References

Metabolic Aggressiveness in Benign Meningiomas with Chromosomal Instabilities

Daniel Monleón, José Manuel Morales, Ana Gonzalez-Segura, et al.

Cancer Res 2010;70:8426-8434. Published OnlineFirst September 21, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1498

Cited articles
This article cites 36 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/21/8426.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/21/8426.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.